Smith & Nephew pioneers `engineered skin' treatment
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.SMITH & NEPHEW, the UK's largest healthcare group, is hoping to introduce a revolutionary new cure for cartilage and ligament injuries based on its pioneering skin-grafting work which uses human tissue from the foreskin of circumcised babies. The new treatment could eventually prevent the amputation of patient's legs and act as alternative to the insertion of artificial knees.
S&N is the first company in the world to develop specially engineered skin, called Dermagraft. It is currently used to help treat foot ulcers in diabetics. Sufferers often lose sensation and have poor blood circulation in their feet, which makes them more susceptible to ulcers. Dermagraft acts a natural cure for the ulcers, providing new skin tissue. Now the company is trying to extend Dermagraft's applications, using the skin to treat leg ulcers and pressure sores. This year it will also start human clinical trials to treat cartilage injuries.
Chris O'Donnell, S&N's chief executive, said: "We have developed an `off the shelf' bio-engineered human skin. It may have a wide variety of uses that could transform our company."
Investment column, page 24
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments